Janux Therapeutics (JANX)
(Real Time Quote from BATS)
$35.68 USD
+0.39 (1.11%)
Updated Aug 8, 2024 09:34 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JANX 35.68 +0.39(1.11%)
Will JANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
Other News for JANX
Janux Therapeutics GAAP EPS of -$0.11 beats by $0.21, revenue of $8.89M beats by $8.03M
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
TD Cowen Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
Janux Therapeutics reports Q2 EPS (11c), consensus (31c)